In non-small cell lung cancer (NSCLC), the EGFR inhibitor gefitinib can achieve remarkable responses, but also induce tetraploidization which leads to p38 mediated drug resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.